ReachRxResearch
Home
Research
Sign Up
XXYLT1 and Mendelian Retinal Dystrophy
Back to Research Hub
  1. Home
  2. Research Hub
  3. XXYLT1 and Mendelian…

XXYLT1 and Mendelian Retinal Dystrophy

JAMA Ophthalmology·July 30Open Access
OphthalmologyPractice changingCone-Rod DystrophyInherited Retinal DiseaseMacular DystrophyGenome-Wide Association Study With Replication Cohort ValidationMixed

Summary

View source

What was studied

A GWAS using the FinnGen cohort (540 IRD cases, 473,945 controls) was performed to discover novel genes linked to inherited retinal disease (IRD), with replication in a Finnish clinical cohort (n=49) and a UK cohort (n=2), conducted January 2024–December 2025.

Key findings

13 recessive loci reached genome-wide significance (P < 5×10⁻⁸); 4 were novel IRD associations, including *XXYLT1* (c.505-1G>C founder variant). In the replication cohort, 5 more homozygous individuals (4 families) were identified; phenotype was cone-rod or macular dystrophy with cystoid macular edema and/or schisis-like changes. RNA sequencing confirmed exon 2 skipping and loss-of-function. Two UK patients carried a distinct homozygous *XXYLT1* missense variant (c.766G>A, p.Glu256Lys).

Study limitations

- Case numbers are small (540 GWAS cases; 7 total replication cases), limiting statistical power for rare variants. - Founder population (Finnish) may limit generalizability of the c.505-1G>C variant to other ethnicities. - Functional studies were RNA-based; no protein-level or animal model validation was reported.

Clinical implications

Clinicians evaluating unsolved IRD cases — especially cone-rod or macular dystrophy with cystoid macular edema or schisis-like findings — should consider adding *XXYLT1* to diagnostic gene panels. GWAS in founder populations is a viable strategy for uncovering rare Mendelian disease genes.

Caveats

  • Functional validation is RNA-level only; no protein biochemistry, animal models, or patient outcome data were reported.
  • Study design is labeled as GWAS with replication; level of evidence (3) reflects controlled observational design without randomization or longitudinal treatment outcomes.
  • The 'practice_changing' impact flag is applied cautiously: this is a gene discovery study, not a therapeutic trial, but the finding directly affects clinical gene panel composition.
Show all 4
  • The total sample size reported combines GWAS cases (540), GWAS controls (473,945), and small replication cohorts (49 Finnish + 2 UK patients) — these groups are not directly comparable and serve different analytical roles.

Related Questions

Explore related topics

Which genes should be included in a comprehensive inherited retinal disease diagnostic panel?What are the clinical features of cone-rod dystrophy with cystoid macular edema in Mendelian disease?How effective is GWAS in founder populations for identifying rare Mendelian disease genes?

Publication Details

Year
2026
Journal
JAMA Ophthalmology
Sample Size
n=474,536
Source
View article
Keep scrolling
More content below.
Up Next